Randi Maria Hanghøj Tei
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Randi Maria Hanghøj Tei has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Anja Fenger Dreyer
Department of Endocrinology and Metabolism, Odense University Hospital, Odense, Denmark
2 shared publications Bente L. Langdahl
Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Palle Juul Jensens Boulevard 99, G317, Aarhus N, 8200, Denmark
2 shared publications- Hajir Al-Jorani
Department of Endocrinology and Metabolism, Odense University Hospital, Odense, Denmark
2 shared publications - Jens Otto Lunde Jørgensen
Department of Endocrinology and Internal Medicine, Aarhus University Hospital , Aarhus 8200
2 shared publications Lise Sofie Bislev
Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Denmark
2 shared publications- Louise Lehmann Christensen
Center for Gender Identity, Department of Endocrinology, Odense University Hospital
2 shared publications
Latest Publications
- Open Access
- 25 June 2026
- Published by SAGE Publications in Cephalalgia Reports
- Vol. 9
Cabergoline for migraine prevention (PROTECT): Protocol for a randomized, placebo-controlled, double-blind trial
Cabergoline, a dopamine receptor agonist, has shown beneficial effects as a preventive treatment for migraine, with no serious adverse events reported. This study aims to evaluate whether cabergoline is superior to placebo in reducing monthly migraine days (MMD), while assessing safety and tolerability. In a randomized, parallel-group, placebo-controlled, double-blind superiority phase II trial, 150 adults with 4–14 MMD will be included. Participants are randomized (1:1:1) to cabergoline 0.5 mg, cabergoline 1.0 mg or placebo once weekly as add-on treatment for 12 weeks. In a 12-week open-label extension, all participants, including those initially assigned to placebo, will be re-randomized (1:1) to cabergoline 0.5 mg or 1.0 mg once weekly to assess sustained effects and safety. The primary outcome is change in MMD from baseline to the final four weeks of the double-blind phase. Key secondary outcomes include ≥50% responder rate, change in the number of moderate-to-severe headache days, acute medication use and patient-reported outcomes (PGIC, HIT-6, MIDAS, WPAI). Exploratory analyses include biomarkers, pharmacogenetics and cost-effectiveness. Analyses will follow the intention-to-treat principle.
- 25 June 2026
- Published by SAGE Publications in Cephalalgia Reports
- Vol. 9
Open AccessCabergoline for migraine prevention (PROTECT): Protocol for a randomized, placebo-controlled, double-blind trial
Cabergoline, a dopamine receptor agonist, has shown beneficial effects as a preventive treatment for migraine, with no serious adverse events reported. This study aims to evaluate whether cabergoline is superior to placebo in reducing monthly migraine days (MMD), while assessing safety and tolerability. In a randomized, parallel-group, placebo-controlled, double-blind superiority phase II trial, 150 adults with 4–14 MMD will be included. Participants are randomized (1:1:1) to cabergoline 0.5 mg, cabergoline 1.0 mg or placebo once weekly as add-on treatment for 12 weeks. In a 12-week open-label extension, all participants, including those initially assigned to placebo, will be re-randomized (1:1) to cabergoline 0.5 mg or 1.0 mg once weekly to assess sustained effects and safety. The primary outcome is change in MMD from baseline to the final four weeks of the double-blind phase. Key secondary outcomes include ≥50% responder rate, change in the number of moderate-to-severe headache days, acute medication use and patient-reported outcomes (PGIC, HIT-6, MIDAS, WPAI). Exploratory analyses include biomarkers, pharmacogenetics and cost-effectiveness. Analyses will follow the intention-to-treat principle.
- Open Access
Effect of supplemental hydrocortisone during stress in prednisolone-induced adrenal insufficiency: a study protocol for a multicentre, randomised, double-blinded, placebo-controlled clinical trial on health-related quality of life in patients with polymyalgia rheumatica/giant cell arteritis on low-dose prednisolone treatment (the RESCUE study)
Introduction Patients on low-dose prednisolone may develop adrenal insufficiency causing reduced health-related quality of life (HRQoL) and increased risk of adrenal crisis. This study examines whether supplemental hydrocortisone during mild to moderate stress improves HRQoL in patients with polymyalgia rheumatica/giant cell arteritis (PMR/GCA) with adrenal insufficiency on low-dose prednisolone. Methods and analysis A multicentre, randomised, double-blinded, placebo-controlled, clinical trial including patients with PMR/GCA receiving ongoing prednisolone ≤5 mg/day. Eligible patients undergo an adrenocorticotropic hormone (ACTH) test, and 250 patients with a stimulated cortisolEthics and dissemination The study is approved by the Ethics Committee of the Capital Region of Denmark and the Danish Medicines Agency. Recruitment began June 2022. The last patient’s last visit is expected in 2026. Results will be disseminated via peer-reviewed publication and conference presentations. Trial registration numbers EudraCT:2021-002528-18, CTIS:2024-518272-30-00, NCT05435781.
Open AccessEffect of supplemental hydrocortisone during stress in prednisolone-induced adrenal insufficiency: a study protocol for a multicentre, randomised, double-blinded, placebo-controlled clinical trial on health-related quality of life in patients with polymyalgia rheumatica/giant cell arteritis on low-dose prednisolone treatment (the RESCUE study)
Introduction Patients on low-dose prednisolone may develop adrenal insufficiency causing reduced health-related quality of life (HRQoL) and increased risk of adrenal crisis. This study examines whether supplemental hydrocortisone during mild to moderate stress improves HRQoL in patients with polymyalgia rheumatica/giant cell arteritis (PMR/GCA) with adrenal insufficiency on low-dose prednisolone. Methods and analysis A multicentre, randomised, double-blinded, placebo-controlled, clinical trial including patients with PMR/GCA receiving ongoing prednisolone ≤5 mg/day. Eligible patients undergo an adrenocorticotropic hormone (ACTH) test, and 250 patients with a stimulated cortisolEthics and dissemination The study is approved by the Ethics Committee of the Capital Region of Denmark and the Danish Medicines Agency. Recruitment began June 2022. The last patient’s last visit is expected in 2026. Results will be disseminated via peer-reviewed publication and conference presentations. Trial registration numbers EudraCT:2021-002528-18, CTIS:2024-518272-30-00, NCT05435781.
- Open Access
Hydrocortisone replacement therapy in patients with glucocorticoid withdrawal syndrome after cessation of glucocorticoid treatment: REPLACE, a multicentre, randomised, double-blinded, placebo-controlled, 16-week study protocol
Introduction: Glucocorticoid therapy is prescribed for a variety of inflammatory conditions and is associated with severe adverse effects. A glucocorticoid withdrawal syndrome (GWS) may occur after prolonged glucocorticoid treatment—with or without biochemical glucocorticoid-induced adrenal insufficiency (GIAI). Previously, GWS was not considered an entity, probably due to the overlap between symptoms of GWS and GIAI. The Addison’s disease-specific quality of life questionnaire (AddiQoL-30) is a validated tool for quantifying symptoms of adrenal insufficiency resembling GWS. In the present study, we test the hypothesis that patients with a low AddiQoL-30 score and/or low cortisol response to a short Synacthen test (SST), after cessation of prednisolone treatment, may benefit from low-dose hydrocortisone therapy without increasing the risk of metabolic and cardiovascular disease during prolonged cortisol exposure. Methods and analysis: REPLACE is a multi-centre, double-blinded, placebo-controlled randomised controlled trial in patients with polymyalgia rheumatica or giant cell arteritis after cessation of prednisolone treatment. Criteria for randomisation are an AddiQoL-30 score ≤85 and/or plasma cortisol response to SST, 30-min p-cortisol >100 and 85; and (2) patients with a SST-stimulated cortisol ≤100 nmol/L. Ethics and dissemination: The study is conducted in accordance with the Declaration of Helsinki, registered at the Clinical Trials Information System (CTIS: 2024-513822-53-00) and Clinicaltrials.gov ( NCT05193396 ), and publications will be in accordance with the recommendations of the International Committee of Medical Journal Editors. The trial is monitored by local independent Good Clinical Practice units and overseen by the Danish Data Protection Agency (journal no. 21/27119), the Regional Committees on Health Research Ethics for Southern Denmark (project ID: S-20210076), the Danish Patient Safety Authority and the Danish Medicines Agency. Trial registration number: NCT05193396 .
Open AccessHydrocortisone replacement therapy in patients with glucocorticoid withdrawal syndrome after cessation of glucocorticoid treatment: REPLACE, a multicentre, randomised, double-blinded, placebo-controlled, 16-week study protocol
Introduction: Glucocorticoid therapy is prescribed for a variety of inflammatory conditions and is associated with severe adverse effects. A glucocorticoid withdrawal syndrome (GWS) may occur after prolonged glucocorticoid treatment—with or without biochemical glucocorticoid-induced adrenal insufficiency (GIAI). Previously, GWS was not considered an entity, probably due to the overlap between symptoms of GWS and GIAI. The Addison’s disease-specific quality of life questionnaire (AddiQoL-30) is a validated tool for quantifying symptoms of adrenal insufficiency resembling GWS. In the present study, we test the hypothesis that patients with a low AddiQoL-30 score and/or low cortisol response to a short Synacthen test (SST), after cessation of prednisolone treatment, may benefit from low-dose hydrocortisone therapy without increasing the risk of metabolic and cardiovascular disease during prolonged cortisol exposure. Methods and analysis: REPLACE is a multi-centre, double-blinded, placebo-controlled randomised controlled trial in patients with polymyalgia rheumatica or giant cell arteritis after cessation of prednisolone treatment. Criteria for randomisation are an AddiQoL-30 score ≤85 and/or plasma cortisol response to SST, 30-min p-cortisol >100 and 85; and (2) patients with a SST-stimulated cortisol ≤100 nmol/L. Ethics and dissemination: The study is conducted in accordance with the Declaration of Helsinki, registered at the Clinical Trials Information System (CTIS: 2024-513822-53-00) and Clinicaltrials.gov ( NCT05193396 ), and publications will be in accordance with the recommendations of the International Committee of Medical Journal Editors. The trial is monitored by local independent Good Clinical Practice units and overseen by the Danish Data Protection Agency (journal no. 21/27119), the Regional Committees on Health Research Ethics for Southern Denmark (project ID: S-20210076), the Danish Patient Safety Authority and the Danish Medicines Agency. Trial registration number: NCT05193396 .
- Open Access
- 4 January 2023
- Published by Wiley in Scandinavian Journal of Caring Sciences
- Vol. 37 (1) , 301-312
A Danish version of the MISSCARE survey: Translation and validation
Background: Measuring missed nursing care in clinical settings may serve as an important indicator for improving patient safety and nursing staff retention. Internationally, several tools exist, with the MISSCARE Survey being the most frequently used and validated; however, no tools are available in the Danish language.Aim: This study aimed at translating the MISSCARE Survey from US English to Danish and evaluate its psychometric properties.Methods: The translation followed the recommended method, that is forward‐and‐backward translation, involving clinical experts and a professional, native English‐speaking translator. The final version was approved by the survey's original developer. Face validity was tested among 10 nurses and 1 practical nurse. Nursing staff from 34 selected departments at Aarhus University Hospital's (n = 1241) were invited to participate in a pilot test in November 2020. The survey consisted of a demographic section, a section of ‘nursing elements’ (Part A) and section of ‘reasons’ (Part B). Acceptability was assessed on Part A and B. Reliability was tested by Cronbach's alpha, and psychometric properties were investigated using Confirmatory Factor Analysis (Part B).Results: The face‐validity test resulted in minor contextual changes and the addition of a ‘not applicable’ response option in Part A. The pilot test had a 42.6% response rate (n = 529). Acceptability was good, with 1–10 missing responses per item in Part A and 0–20 missing responses in Part B. The numbers of ‘not applicable’ responses ranged from 0 to 81. The overall Cronbach's alpha was 0.81. Factor‐loading ranges were 0.62–0.48 for ‘communication’, 0.79–0.39 for ‘materials and resources’, and 0.50–0.35 for ‘labour’, suggesting an acceptable fit with the theoretical model.Conclusion: The MISSCARE Survey was successfully translated into Danish. The psychometric properties confirmed the questionnaire as a valid and reliable tool for measuring missed nursing care in Danish hospital settings.
- 4 January 2023
- Published by Wiley in Scandinavian Journal of Caring Sciences
- Vol. 37 (1) , 301-312
Open AccessA Danish version of the MISSCARE survey: Translation and validation
Background: Measuring missed nursing care in clinical settings may serve as an important indicator for improving patient safety and nursing staff retention. Internationally, several tools exist, with the MISSCARE Survey being the most frequently used and validated; however, no tools are available in the Danish language.Aim: This study aimed at translating the MISSCARE Survey from US English to Danish and evaluate its psychometric properties.Methods: The translation followed the recommended method, that is forward‐and‐backward translation, involving clinical experts and a professional, native English‐speaking translator. The final version was approved by the survey's original developer. Face validity was tested among 10 nurses and 1 practical nurse. Nursing staff from 34 selected departments at Aarhus University Hospital's (n = 1241) were invited to participate in a pilot test in November 2020. The survey consisted of a demographic section, a section of ‘nursing elements’ (Part A) and section of ‘reasons’ (Part B). Acceptability was assessed on Part A and B. Reliability was tested by Cronbach's alpha, and psychometric properties were investigated using Confirmatory Factor Analysis (Part B).Results: The face‐validity test resulted in minor contextual changes and the addition of a ‘not applicable’ response option in Part A. The pilot test had a 42.6% response rate (n = 529). Acceptability was good, with 1–10 missing responses per item in Part A and 0–20 missing responses in Part B. The numbers of ‘not applicable’ responses ranged from 0 to 81. The overall Cronbach's alpha was 0.81. Factor‐loading ranges were 0.62–0.48 for ‘communication’, 0.79–0.39 for ‘materials and resources’, and 0.50–0.35 for ‘labour’, suggesting an acceptable fit with the theoretical model.Conclusion: The MISSCARE Survey was successfully translated into Danish. The psychometric properties confirmed the questionnaire as a valid and reliable tool for measuring missed nursing care in Danish hospital settings.
- 19 February 2019
- Published by Springer Nature in Calcified Tissue International
- Vol. 104 (6) , 641-649
An Optimised Fracture Liaison Service Model: Maintained Diagnostic Sensitivity Despite Reduced Number of Diagnostic Tests Performed
Patients suffering a low-energy fracture are at high risk of subsequent fractures. Investigation of all fragility fracture patients above the age of 50 years is recommended in order to prevent further fractures. The aim of this study was to investigate alternative strategies including known risk factors (age, sex, and body weight) for selecting fracture patients for osteoporosis assessment and investigate how these strategies would affect the proportion of patients with osteoporosis identified and the number of patients referred for Dual X-ray Absorptiometry (DXA) compared with the original FLS strategy. From OFELIA; a cohort study comprising 794 fragility fracture patients we included 622 patients aged 18 + years (mean age 56 ± 17) with fragility fractures. We investigated the predictive value of clinical risk factors using ROC curves and AUC analyses. The revised strategies were compared by analyzing sensitivity and specificity of different strategies based on sex, age, BMI, and bodyweight. For patients 50 + years, a strategy investigating men and women with body weight ≤ 85 kg resulted in sensitivity and specificity of 94% and 25%, respectively, reducing the number of DXAs by 21%. For patients < 50 years, the prevalence of osteoporosis was low and it was, therefore, difficult to develop an acceptable strategy. We found that the original FLS strategy can be modified to include substantially fewer patients and still only miss the osteoporosis diagnosis in a very few patients. A modified strategy would potentially save costs and concerns in many patients.
- 19 February 2019
- Published by Springer Nature in Calcified Tissue International
- Vol. 104 (6) , 641-649
An Optimised Fracture Liaison Service Model: Maintained Diagnostic Sensitivity Despite Reduced Number of Diagnostic Tests Performed
Patients suffering a low-energy fracture are at high risk of subsequent fractures. Investigation of all fragility fracture patients above the age of 50 years is recommended in order to prevent further fractures. The aim of this study was to investigate alternative strategies including known risk factors (age, sex, and body weight) for selecting fracture patients for osteoporosis assessment and investigate how these strategies would affect the proportion of patients with osteoporosis identified and the number of patients referred for Dual X-ray Absorptiometry (DXA) compared with the original FLS strategy. From OFELIA; a cohort study comprising 794 fragility fracture patients we included 622 patients aged 18 + years (mean age 56 ± 17) with fragility fractures. We investigated the predictive value of clinical risk factors using ROC curves and AUC analyses. The revised strategies were compared by analyzing sensitivity and specificity of different strategies based on sex, age, BMI, and bodyweight. For patients 50 + years, a strategy investigating men and women with body weight ≤ 85 kg resulted in sensitivity and specificity of 94% and 25%, respectively, reducing the number of DXAs by 21%. For patients < 50 years, the prevalence of osteoporosis was low and it was, therefore, difficult to develop an acceptable strategy. We found that the original FLS strategy can be modified to include substantially fewer patients and still only miss the osteoporosis diagnosis in a very few patients. A modified strategy would potentially save costs and concerns in many patients.
- 17 September 2018
- Published by Springer Nature in Calcified Tissue International
- Vol. 104 (1) , 102-114
OFELIA: Prevalence of Osteoporosis in Fragility Fracture Patients
Worldwide, a care gap has been recognized between presenting with a fracture and prevention of the next fracture. Fracture Liaison Service is the most cost-effective method to close this gap, but its implementation is sparse in the Nordic countries. To assess the need for a fracture prevention program, the primary aim of this study was to estimate the prevalence of osteoporosis in patients treated for fragility fractures at Aarhus University Hospital, Denmark. Secondary aims were to identify clinical risk factors associated with osteoporosis and the up-take of anti-osteoporosis treatment. The study was conducted as a cross-sectional study and patients aged 18+ years were consecutively identified over a 12 months period. Of 1164 identified patients, 832 were included and 794 (70% women, 66% aged ≥ 50 years) patients completed the study. Bone mineral density was measured by DXA and information about clinical risk factors were obtained. The overall prevalence of osteoporosis in this cohort was 14.9%, increasing to 20.3% in patients ≥ 50 years (22.9% in women, 9.6% in men). In addition to age above 50 years, female sex, low BMI, and early menopause were significantly associated with osteoporosis. At 3-years follow-up in patients diagnosed with osteoporosis, 95% of patients who initiated anti-osteoporosis treatment after their fracture were still adherent to treatment. Given that osteoporosis was demonstrated in one in five fragility fracture patients above 50 years, OFELIA stresses the need for implementation of a program aiming at securing appropriate investigation and treatment of osteoporosis in patients presenting a fragility fracture.
- 17 September 2018
- Published by Springer Nature in Calcified Tissue International
- Vol. 104 (1) , 102-114
OFELIA: Prevalence of Osteoporosis in Fragility Fracture Patients
Worldwide, a care gap has been recognized between presenting with a fracture and prevention of the next fracture. Fracture Liaison Service is the most cost-effective method to close this gap, but its implementation is sparse in the Nordic countries. To assess the need for a fracture prevention program, the primary aim of this study was to estimate the prevalence of osteoporosis in patients treated for fragility fractures at Aarhus University Hospital, Denmark. Secondary aims were to identify clinical risk factors associated with osteoporosis and the up-take of anti-osteoporosis treatment. The study was conducted as a cross-sectional study and patients aged 18+ years were consecutively identified over a 12 months period. Of 1164 identified patients, 832 were included and 794 (70% women, 66% aged ≥ 50 years) patients completed the study. Bone mineral density was measured by DXA and information about clinical risk factors were obtained. The overall prevalence of osteoporosis in this cohort was 14.9%, increasing to 20.3% in patients ≥ 50 years (22.9% in women, 9.6% in men). In addition to age above 50 years, female sex, low BMI, and early menopause were significantly associated with osteoporosis. At 3-years follow-up in patients diagnosed with osteoporosis, 95% of patients who initiated anti-osteoporosis treatment after their fracture were still adherent to treatment. Given that osteoporosis was demonstrated in one in five fragility fracture patients above 50 years, OFELIA stresses the need for implementation of a program aiming at securing appropriate investigation and treatment of osteoporosis in patients presenting a fragility fracture.
- 29 February 2012
- Published by Scandinavian University Press in Nordisk sygeplejeforskning
- Vol. 2 (1) , 3-14
Inadequate postoperative pain relief in chronic pain patients – A Qualitative Study
Postoperative pain relief is especially challenging in chronic pain patients. Some of these patients are already using strong analgesics, including opioids, before surgery, and may have markedly increased opioid requirements after surgery. In addition, they often need special psychological attention. Only few studies have, however, focused on the patients perspectives. The aim of this study was to describe self-reported experiences of inadequate pain relief after surgery in a group of chronic pain patients. Eight patients with chronic pain who had reported having experienced inadequate pain relief after surgery were interviewed using a semi-structured interview guide 1-2 weeks after discharge from hospital. Meaning condensation and interpretation were used in the analysis according to the approach of Kvale and Brinkmann. Three major themes emerged from the condensation and interpretation of the natural meaning units: 1) distrust towards the patient, 2) disrespect towards the patient, and 3) lack of knowledge about pain treatment among health care professionals. Our findings indicate a lack of knowledge of pain management in chronic pain patients. Special training of health care professionals is required in order to improve pain relief after surgery and, ultimately, patient satisfaction and quality of care in this vulnerable group of patients.
- 29 February 2012
- Published by Scandinavian University Press in Nordisk sygeplejeforskning
- Vol. 2 (1) , 3-14
Inadequate postoperative pain relief in chronic pain patients – A Qualitative Study
Postoperative pain relief is especially challenging in chronic pain patients. Some of these patients are already using strong analgesics, including opioids, before surgery, and may have markedly increased opioid requirements after surgery. In addition, they often need special psychological attention. Only few studies have, however, focused on the patients perspectives. The aim of this study was to describe self-reported experiences of inadequate pain relief after surgery in a group of chronic pain patients. Eight patients with chronic pain who had reported having experienced inadequate pain relief after surgery were interviewed using a semi-structured interview guide 1-2 weeks after discharge from hospital. Meaning condensation and interpretation were used in the analysis according to the approach of Kvale and Brinkmann. Three major themes emerged from the condensation and interpretation of the natural meaning units: 1) distrust towards the patient, 2) disrespect towards the patient, and 3) lack of knowledge about pain treatment among health care professionals. Our findings indicate a lack of knowledge of pain management in chronic pain patients. Special training of health care professionals is required in order to improve pain relief after surgery and, ultimately, patient satisfaction and quality of care in this vulnerable group of patients.